Ionis Pharmaceuticals annual ebitda margin
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ionis Pharmaceuticals EBITDA Margin Growth & History (IONS)
Ionis Pharmaceuticals's ebitda margin was −39.13% for fiscal 2025.
View full Ionis Pharmaceuticals company overviewIonis Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −39.13% | +26.55 pp |
| 2024 | 2024-12-31 | −65.68% | −22.40 pp |
| 2023 | 2023-12-31 | −43.28% | +23.71 pp |
| 2022 | 2022-12-31 | −66.99% | −65.46 pp |
| 2021 | 2021-12-31 | −1.52% | +19.96 pp |
| 2020 | 2020-12-31 | −21.48% | −55.36 pp |
| 2019 | 2019-12-31 | 33.88% | +42.02 pp |
| 2018 | 2018-12-31 | −8.15% | −15.81 pp |
| 2017 | 2017-12-31 | 7.66% | +10.65 pp |
| 2016 | 2016-12-31 | −2.98% | +21.26 pp |
| 2015 | 2015-12-31 | −24.24% | −4.94 pp |
| 2014 | 2014-12-31 | −19.31% | +11.30 pp |
| 2013 | 2013-12-31 | −30.60% | +30.00 pp |
| 2012 | 2012-12-31 | −60.61% | +4.49 pp |
| 2011 | 2011-12-31 | −65.10% | −24.98 pp |
| 2010 | 2010-12-31 | −40.12% | −20.71 pp |
| 2009 | 2009-12-31 | −19.41% | −9.90 pp |
| 2008 | 2008-12-31 | −9.51% | — |
Ionis Pharmaceuticals quarterly ebitda margin
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −36.63% | −68.20 pp |
| Q1 2026 | 2026-03-31 | −46.11% | +63.34 pp |
| Q4 2025 | 2025-12-31 | −103.56% | −55.84 pp |
| Q3 2025 | 2025-09-30 | −100.37% | +8.49 pp |
| Q2 2025 | 2025-06-30 | 31.56% | +59.53 pp |
| Q1 2025 | 2025-03-31 | −109.45% | +13.00 pp |
| Q4 2024 | 2024-12-31 | −47.72% | −46.82 pp |
| Q3 2024 | 2024-09-30 | −108.87% | −11.73 pp |
| Q2 2024 | 2024-06-30 | −27.97% | +18.17 pp |
| Q1 2024 | 2024-03-31 | −122.45% | −37.46 pp |
| Q4 2023 | 2023-12-31 | −0.90% | +133.66 pp |
| Q3 2023 | 2023-09-30 | −97.14% | −62.88 pp |
| Q2 2023 | 2023-06-30 | −46.14% | +14.49 pp |
| Q1 2023 | 2023-03-31 | −84.99% | −47.50 pp |
| Q4 2022 | 2022-12-31 | −134.56% | −185.70 pp |
| Q3 2022 | 2022-09-30 | −34.26% | +27.00 pp |
| Q2 2022 | 2022-06-30 | −60.64% | −6.29 pp |
| Q1 2022 | 2022-03-31 | −37.49% | +40.92 pp |
| Q4 2021 | 2021-12-31 | 51.14% | +57.51 pp |
| Q3 2021 | 2021-09-30 | −61.26% | −40.86 pp |
| Q2 2021 | 2021-06-30 | −54.35% | −21.29 pp |
| Q1 2021 | 2021-03-31 | −78.41% | −35.36 pp |
| Q4 2020 | 2020-12-31 | −6.36% | −59.97 pp |
| Q3 2020 | 2020-09-30 | −20.40% | −23.86 pp |
| Q2 2020 | 2020-06-30 | −33.06% | −23.80 pp |
| Q1 2020 | 2020-03-31 | −43.05% | −85.13 pp |
| Q4 2019 | 2019-12-31 | 53.60% | +46.16 pp |
| Q3 2019 | 2019-09-30 | 3.46% | +13.99 pp |
| Q2 2019 | 2019-06-30 | −9.26% | +30.94 pp |
| Q1 2019 | 2019-03-31 | 42.08% | +42.43 pp |
| Q4 2018 | 2018-12-31 | 7.45% | +9.82 pp |
| Q3 2018 | 2018-09-30 | −10.54% | −21.91 pp |
| Q2 2018 | 2018-06-30 | −40.20% | −47.73 pp |
| Q1 2018 | 2018-03-31 | −0.34% | −18.88 pp |
| Q4 2017 | 2017-12-31 | −2.38% | — |
| Q3 2017 | 2017-09-30 | 11.38% | −4.84 pp |
| Q2 2017 | 2017-06-30 | 7.54% | +129.85 pp |
| Q1 2017 | 2017-03-31 | 18.54% | +161.76 pp |
| Q3 2016 | 2016-09-30 | 16.21% | +110.58 pp |
| Q2 2016 | 2016-06-30 | −122.31% | −160.91 pp |
| Q1 2016 | 2016-03-31 | −143.22% | −130.82 pp |
| Q4 2015 | 2015-12-31 | −118.57% | −132.32 pp |
| Q3 2015 | 2015-09-30 | −94.37% | −49.33 pp |
| Q2 2015 | 2015-06-30 | 38.60% | +47.48 pp |
| Q1 2015 | 2015-03-31 | −12.40% | +87.41 pp |
| Q4 2014 | 2014-12-31 | 13.75% | +56.98 pp |
| Q3 2014 | 2014-09-30 | −45.03% | +56.24 pp |
| Q2 2014 | 2014-06-30 | −8.88% | +7.55 pp |
| Q1 2014 | 2014-03-31 | −99.80% | −107.49 pp |
| Q4 2013 | 2013-12-31 | −43.23% | — |
| Q3 2013 | 2013-09-30 | −101.27% | — |
| Q2 2013 | 2013-06-30 | −16.43% | — |
| Q1 2013 | 2013-03-31 | 7.68% | — |
Ionis Pharmaceuticals ebitda margin trends
Over the last five fiscal years, Ionis Pharmaceuticals's ebitda margin decreased from −21.48% to −39.13%, a change of −17.65 percentage points. The latest reported quarter, Q2 2026, shows −36.63%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ionis Pharmaceuticals source filings ↗Community posts
Roche quantifies proteinuria reduction for Ionis-licensed sefaxersen
Ionis ($IONS) reported new detailed results from partner Roche’s Phase 3 IMAgINATION trial of sefaxersen in IgA nephropathy. The investigational monthly injection reduced urine protein-to-creatinine ratio by 43.1% versus placebo at 37 weeks ...
